Observational studyInternational urology and nephrology2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.
Kazutaka Nakamura et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.